Biopeople

Biotech ace joins Abzena

Biotech ace joins Abzena

30.03.2015 - Life Sciences company Abzena has appointed biotechnology expert Jim Mills as its Vice President of Technical Operations. The Cambridge-based company provides services and technologies that enable the development of biopharmaceutical products.

John brings a wealth of experience in the fields of biotechnology and biochemistry. Before joining Abzena in March, he held the position of CEO of Cantab Biopharmaceuticals, which he joined in 1997, initially to work in process development. Whilst at Cantab he took on roles of increasing levels of responsibility in biopharmaceutical manufacturing before becoming Director of Operations following the acquisition of Cantab by Xenova in 2007. In 2010, he took the helm as CEO when the company was taken over by Celtic Pharma Holdings.

“We are delighted to welcome Jim to Abzena and I look forward to working with him as the Company continues its commercial and corporate development,” said John Burt, CEO of Abzena.

In his new position as Vice President of Technical Operations, Jim will take on a lead role in the development of the Group’s strategy to support its partners’ access to Abzena’s technologies for biopharmaceutical development, as well as providing support for the commercial activities of the group. 

http://www.european-biotechnology-news.com/people/bio-people/2015/jim-mills.html

11.02.2015 Eliot Forster has taken over the lead of British biologics specialist Immunocore Limited. The new CEO succeeds founder James Noble who stood down to become full-time CEO of sister company Adaptimmune.

© Immunocore

Forster is joining from Italian biotech Creabilis, where he also held the role of CEO since 2010. Prior to that, he worked in leading roles at Solace Pharmaceuticals, Pfizer and Glaxosmithkline. Forster is also Chairman of the MedCity project, launched last year to grow a world-leading life sciences cluster in and around London.

03.02.2015 Darrin Disley, Horizon Discovery’s CEO has won the Entrepreneur of the Year award at the Quoted Company Awards 2015 in London.

© Horizon Discovery

The Quoted Company Awards, now in its 11th year, recognises the achievements of quoted companies listed outside of the FTSE 350 and their key directors.

Darrin has overseen a transformational year for the Cambridge-based biotech, which supplies research tools and services to organisations engaged in genomics research and the development of personalised medicines. Within a year, Horizon has transitioned from a private UK life science business to a publicly listed international life science group with facilities located in the UK, Austria and the US. Under Darrin’s leadership, Horizon was listed on AIM market or the London Stock Exchange in March 2014. The company raised £68.6m, almost three times the initial target.

In 2012, he was named Business Leader of the Year at the European Life Science Awards. In addition to his role at Horizon, Darrin is also an active entrepreneur and leader in the life science community, where he invests and provides guidance and mentoring to help develop promising young companies.

29.01.2015 MedDay Pharmaceuticals has appointed Philippe Goupit as an independent Non-Executive Director on its board of directors. Mr Goupit brings his significant business and corporate development experience in the biotech and pharma sector to the Parisian-based company, which focuses on the treatment of nervous system disorders.

© MedDay Pharmaceuticals

Philippe, a pharma VIP has over 30 years’ experience in the industry, and has spent 20 years at Sanofi. Until recently he was Vice President, Corporate Licenses at Sanofi. His experience in business development covers M&A, as former head of the corporate M&A group in Sanofi, and licensing activities. Philippe has also served for some years as the Head of Investor Relations at Sanofi.

“Philippe’s broad experience will be hugely beneficial to MedDay as the Company continues to develop its pipeline of assets which address areas of unmet need in neurological and psychiatric diseases, through brain metabolism. Through his experience Philippe will contribute to MedDay’s corporate and business development strategy.”

27.01.2015 On 1 January, Ulla Ruotsalainen was appointed by the board of the TYY Foundation as Vice President of research activities at Tampere University of Technology (TUT), where she will oversee the development of research activities at the university.

© Hovione

With her vast wealth of experience, Ulla has had a long career working for a research institution, the corporate world, a health care unit and the Academy of Finland. She has also served two terms as the Dean of the Faculty of Computing and Electrical Engineering and sat on the Academy of Finland’s Research Council for Natural Sciences and Engineering.

Ruotsalainen places a high value on international research collaboration that cuts across disciplinary boundaries. “The building blocks of a high-quality research environment are a supportive atmosphere that encourages the exploration of new avenues for research and up-to-date equipment,” she says.

Her appointment as Vice President will run until 31 December 2016.

23.01.2015 Filipe Gaspar has been appointed Vice President of Research and Development at the Portuguese pharmaceutical ingredient manufacturer Hovione.

© Hovione

The chemical engineer has worked at Hovione for the last eleven years, mostly in particle engineering, but most recently in a business development role. Gaspar is co-author and co-inventor of numerous publications, scientific presentations and patents.

“For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver,” commented Hovione CEO Guy Villax.

21.01.2015 Fredrik Lindgren is the new CEO and president of Swedish clinical stage drug development company Hansa Medical.

© Hansa Medical

He replaces Emanuel Björne, who has led the company since it was established and takes over the role of Corporate Development Director. Lindgren, who holds a law degree from Lund University, has previously held the position of CEO at Karo Bio and Biolin Scientific. He is chairman and member of the board of Prostalund, Larodan Fine Chemicals and Exini Diagnostics.

19.01.2015 Slovenian chemist Tina Trdan Lušin has been honoured with the Pregl Award for outstanding doctoral work, a price annually conferred by the National Institute of Chemistry Slovenia.

© Pliva

Lušin, a researcher at the Sandoz Development Center, studied pharmacogenetic aspects of metabolism and transport of selective estrogen receptor modulators. With her work, the award committee said, Lušin "established the reason for inter-individual variability in the response to selective estrogen receptor modulators and thereby gained new information for treatment, which could be used in clinical practice."

15.01.2015 On 15 December 2014 Moberg Pharma AB welcomed Jeff Vernimb as its new General Manager for its US operations. He also became a member of the Swedish pharmaceutical company’s Management Team.

© Moberg Pharma

With more than 25 years of experience in consumer health products marketing and sales across multi-national and smaller entrepreneurial businesses, Jeff will help increase the Stockholm-based company’s US business. Prior to joining Moberg, Jeff was Vice President of sales and a member of the senior management team with Insight Pharmaceuticals. In addition to his position at Insight, he has held senior level positions at Dynova Laboratories, Cardinal Health, Novartis Consumer and Pfizer/Warner Lambert.

“It is a pleasure to welcome Jeff to the Management Team at Moberg. I look forward to working together to continue driving the growth of our US business,” said Peter Wolpert, CEO of Moberg Pharma AB.

13.01.2014 French biopharma Pharnext has nominated pharmaceutical and biotechnology industry executive Michel de Rosen to its Board of Directors as it sets its sights on expanding the company’s new therapeutics development, both nationally and internationally.

© Pharnext

Michel de Rosen has a wealth of experience in the sector, holding various executive positions for nearly 25 years at Rhone-Poulenc, in particular its pharmaceutical subsidiary Rhone-Poulenc Rorer, now known as Sanofi. While at Rhone-Poulenc, from 1983 to 1999, Michel served as president and CEO of Pharmuka, Rhone-Poulenc Fibers and Polymers, and then Rhone-Poulenc in the US. Post Rhone-Poulenc, he was CEO of ViroPharma, which was bought by Shire in 2014. After 15 years in the States, Michel returned to France and has been CEO of Eutelsat Communications since 2009.

“Michel de Rosen’s nomination to our board falls within our wish to accelerate Pharnext’s development both in France and abroad. His international expertise will prove valuable to us in our development dynamics,” said Daniel Cohen, chairman and CEO of Pharnext.

06.01.2014 Belgian Biotech FlandersBio has appointed Erwin Blomsma as its new chairman to continue the development of the company’s new strategy, which it intends to roll out both locally and globally.

© Okapi

Erwin started his career after a post-doctoral study at the University of Leuven in Belgium at Janssen Pharmaceutica in 1996 as Technology Manager. In 2000, he co-founded a contract research organisation Crystallice, which was later absorbed by another CRO, Avantium Technologies, where he became VP Technology in 2001 and COO in 2004. In 2007, Dr Blomsma co-founded and became CEO of Okapi Sciences, a company focused on animal health. Okapi Sciences developed a healthy pipeline of veterinary drugs, one of which was licensed to Novartis Animal Health in 2013. Since March 2014, he has been the general manager of Aratana Therapeutics NV in Leuven and VP of Aratana Therapeutics Inc.

“I am honoured to take up the task to lead FlandersBio into a next stage of growth and expansion,” said Erwin. “We will fully continue to develop the synergies with micro-electronics, ICT, medical technology and novel industrial and food applications in this further growth.”

Vorherige Seite2/25Nächste Seite

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week

Products

Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015

Current issue

All issues